Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

Scientists in industry and academia were shocked and saddened to hear of the sudden passing of Bruce Albala. Albala died in Greece on October 16 while celebrating his 40th wedding anniversary with his ...

PhD, National University of Singapore Postdoctoral fellow, University of Oxford Postdoctoral fellow, National Institutes of Health ...

Multiple due dates; see announcement.

SORL1 knockout, knockin, and transgenic mice are now in the Research Models database. The database will be updated as more models become available.